McKesson Stock Price, News & Analysis

McKesson Corporation (NYSE: MCK) has announced plans to host an Investor Day event on September 23, 2025, in New York City. The event will feature presentations from the company's leadership team, including a Q&A session with CEO Brian Tyler and CFO Britt Vitalone. During the event, management will discuss McKesson's strategic priorities, growth strategies, and provide insights into the company's business outlook. Investors and interested parties can access a live webcast of the event and subsequent replay, along with presentation materials, through McKesson's Investor Relations website at investor.mckesson.com.

McKesson Corporation (NYSE: MCK) has completed the acquisition of a controlling interest in Core Ventures, a business services organization established by Florida Cancer Specialists & Research Institute (FCS). McKesson acquired approximately 70% stake in Core Ventures for $2.49 billion, while FCS physicians retained about 30% ownership. The strategic acquisition strengthens McKesson's position in community-based oncology care and expands The US Oncology Network. FCS, which operates across nearly 100 locations in Florida with more than 250 physicians and 280 advanced practice providers, will maintain independent ownership while joining The US Oncology Network. This acquisition aims to accelerate clinical development, improve patient outcomes, and expand access to quality cancer care in local communities.

McKesson Corporation (MCK) has announced its fiscal 2025 fourth quarter and full year financial results, along with fiscal 2026 guidance. The company also revealed plans to separate its Medical-Surgical Solutions business. The financial results and related materials are available on McKesson's Investor Relations website. The company has scheduled a live webcast earnings conference call for investors on May 8th at 4:30 PM ET to discuss the results. Investors can access the earnings press release, financial tables, slide presentation, and audio webcast through McKesson's Investor Relations portal.

McKesson (NYSE: MCK) has completed its acquisition of a controlling interest in PRISM Vision Holdings, a leading provider of ophthalmology and retina management services. The transaction values at approximately $850 million for an 80% stake, while PRISM physicians retain the remaining 20% interest.

The strategic acquisition aims to establish McKesson as a leading platform in retinal and ophthalmology services, enhancing its differentiated value proposition, clinical services, and distribution offerings. The company also announced it will release its fourth quarter and full year fiscal 2025 financial results after market close on May 8, 2025, followed by an earnings conference call at 4:30 PM Eastern Time.

McKesson (NYSE: MCK) has announced its financial results for the third quarter of fiscal year 2025. The company has also raised its full-year adjusted EPS guidance. The detailed financial results are available on McKesson's Investor Relations website. The company is hosting a live webcast earnings conference call on February 5th at 4:30 PM ET to discuss the results with investors. The webcast, earnings release, financial tables, and presentation slides will be accessible on McKesson's Investor Relations platform.

McKesson (NYSE: MCK) has announced a definitive agreement to acquire an 80% controlling interest in PRISM Vision Holdings for approximately $850 million. PRISM Vision physicians will retain the remaining 20% interest. PRISM Vision is a premier provider of general ophthalmology and retina management services, operating with more than 180 providers across 91 office locations and seven ambulatory surgery centers.

The acquisition will be consolidated within McKesson's U.S. Pharmaceutical segment and is expected to be $0.20 to $0.30 accretive to McKesson's Adjusted Earnings Per Diluted Share in the first 12 months, growing to $0.65 to $0.75 by the end of the third year. The transaction aims to strengthen McKesson's position in retina and ophthalmology care, expand data and analytics capabilities, and enhance clinical research opportunities.

McKesson (NYSE:MCK) has announced its Board of Directors has declared a quarterly dividend of $0.71 per share of common stock. The dividend will be distributed to shareholders of record as of March 3, 2025, with the payment scheduled for April 1, 2025.

McKesson (NYSE: MCK) has successfully completed the divestiture of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm, on December 30, 2024. The transaction, which was initially announced in September 2024, aligns with McKesson's strategic focus on capital deployment and prioritization of investments in expanding its oncology and biopharma growth platforms.